Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 86, Issue 1, 2009, Pages 37-43

  Hartemann Heurtier, Agnès ^a,b   Halbron, Marine ^b   Golmard, Jean Louis ^a,b   Jacqueminet, Sophie ^b   Bastard, Jean Philippe ^a,c   Rouault, Christine ^b,d   Ayed, Amine ^b   Pieroni, Laurence ^a,b   Clément, Karine ^a,b,d   Grimaldi, André ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Abdominal fat; Inflammation; Insulin therapy; Pioglitazone; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN A1C; ISOPHANE INSULIN; MESSENGER RNA; METFORMIN; PIOGLITAZONE; SULFONYLUREA; UMULINE NPH; UNCLASSIFIED DRUG;

ABDOMINAL FAT; ADD ON THERAPY; ADIPOSE TISSUE; ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; GENE EXPRESSION REGULATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLAMMATION; INSULIN TREATMENT; INTRAABDOMINAL FAT; LIPID STORAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS FAT; WEIGHT GAIN;

ADIPOSE TISSUE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BODY COMPOSITION; BODY WEIGHT; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MALE; METFORMIN; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 69949121665     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.06.028     Document Type: Article

References (36)

1. Rexrode K.M., Carey V.J., Hennekens C.H., Walters E.E., Colditz G.A., Stampfer M.J., et al. Abdominal adiposity and coronary heart disease in women. JAMA 280 (1998) 1843-1848
2. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
3. St-Pierre J., Lemieux I., Perron P., Brisson D., Santuré M., Vohl M.C., et al. Relation of the "hypertriglyceridemic waist" phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am. J. Cardiol. 99 (2007) 369-373
4. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J. Intern. Med. 252 (2002) 283-294
5. Natali A., Toschi E., Baldeweg S., Ciociaro D., Favilla S., Saccà L., et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 55 (2006) 1133-1140
6. Rosenstock J., Sugimoto D., Strange P., Stewart J.A., Soltes-Rak E., and Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29 (2006) 554-559
7. Cnop M., Landchild M.J., Vidal J., Havel P.J., Knowles N.G., Carr D.R., et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51 (2002) 1005-1015
8. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87 (2002) 2784-2791
9. Smith S.R., De Jonge L., Volaufova J., Li Y., Xie H., and Bray G.A. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 54 (2005) 24-32
10. Carey D.G., Cowin G.J., Galloway G.J., Jones N.P., Richards J.C., Biswas N., et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. Obes. Res. 10 (2002) 1008-1015
11. Basu A., Jensen M.D., McCann F., Mukhopadhyay D., Joyner M.J., and Rizza R.A. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 29 (2006) 510-514
12. MÃkimattila S., Nikkilà K., and Yki-JÃrvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 42 (1999) 406-412
13. Sallé A., Guilloteau G., Ryan M., Bouhanick B., and Ritz P. Effect of insulin treatment on the body composition of Type 2 diabetic patients. Diabet. Med. 21 (2004) 1298-1303
14. Juurinen L., Tiikkainen M., HÃkkinen A.M., Hakkarainen A., and Yki-JÃrvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E829-835
15. Inadera H., Ito S., Ishikawa Y., Shinomiya M., Shirai K., Saito Y., et al. Visceral fat deposition is seen in patients with insulinoma. Diabetologia 36 (1993) 91
16. Leinonen E., Hurt-Camejo E., Wiklund O., HultÃn L.M., Hiukka A., and Taskinen M.R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166 (2003) 387-394
17. Fain J.N., Madan A.K., Hiler M.L., Cheema P., and Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145 (2004) 2273-2282
18. Kern P.A., Di Gregorio G.B., Lu T., Rassouli N., and Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 52 (2003) 1779-1785
19. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004) 813-823
20. Shoelson S.E., Lee J., and Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 116 (2006) 1793-1801
21. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17 (2006) 4-12
22. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112 (2003) 1821-1830
23. Kolak M., Yki-Järvinen H., Kannisto K., Tiikkainen M., Hamsten A., Eriksson P., et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 92 (2007) 720-724
24. Reynolds L.R., Kingsley F.J., Karounos D.G., and Tannock L.R. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res. Clin. Pract. 77 (2007) 180-187
25. Fernandez M., Triplitt C., Wajcberg E., Sriwijilkamol A.A., Musi N., Cusi K., et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 31 (2008) 121-217
26. Avilés-Santa L., Salinas K., Adams-Huet B., and Raskin P. Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus. J. Invest. Med. 54 (2006) 20-31
27. Akazawa S., Sun F., Ito M., Kawasaki E., and Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23 (2000) 1067-1071
28. Kuk J.L., Church T.S., Blair S.N., and Ross R. Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome?. Diabetes Care 29 (2006) 679-684
29. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89 (2004) 2728-2735
30. Ghanim H., Dhindsa S., Aljada A., Chaudhuri A., Viswanathan P., and Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J. Clin. Endocrinol. Metab. 91 (2006) 3553-3558
31. Tonelli J., Li W., Kishore P., Pajvani U.B., Kwon E., Weaver C., et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53 (2004) 1621-1629
32. Iwasaki T., Nakajima A., Yoneda M., Yamada Y., Mukasa K., Fujita K., et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 28 (2005) 2486-2491
33. Tiikkainen M., HÃkkinen A.M., Korsheninnikova E., Nyman T., MÃkimattila S., and Yki-JÃrvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
34. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
35. Andersson C.X., Sopasakis V.R., Wallerstedt E., and Smith U. Insulin antagonizes interleukin-6 signaling and is anti-inflammatory in 3T3-L1 adipocytes. J. Biol. Chem. 282 (2007) 9430-9435
36. Viardot A., Grey S.T., Mackay F., and Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology 148 (2007) 346-353